Catalog No.
DHG11002
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
Tumor necrosis factor receptor superfamily member 9, CD137, 4-1BB ligand receptor, CDw137, TNFRSF9, T-cell antigen ILA, T-cell antigen 4-1BB homolog, ILA
Concentration
1.52 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q07011
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.94mM Citric acid, 16.7mM Trisodium citrate dihydrate, 6.2% sucrose, pH 6.5,0.01% Tween 80
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BMS-663513, CAS: 934823-49-1
Clone ID
Urelumab
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma, PMID: 32052473
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab, PMID: 30410017
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody, PMID: 27756788
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice, PMID: 26113085
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies, PMID: 29118009
Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells, PMID: 31143521
Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity, PMID: 31105267
Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity, PMID: 31974274
4-1BB costimulation promotes bystander activation of human CD8 T cells, PMID: 33180337
CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer, PMID: 27496866
Checkpoint Inhibition in Non-Hodgkin's Lymphoma, PMID: 29065421
Phase I Study of Stereotactic Body Radiotherapy Plus Nivolumab and Urelumab or Cabiralizumab in Patients with Advanced Solid Tumors, PMID: 34168049
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment, PMID: 23452415
CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development, PMID: 34064598
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications, PMID: 26137403
CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8 + T Cell-Relevant Genes, PMID: 29133290
Functional expression of CD137 (4-1BB) on T helper follicular cells, PMID: 26587331
Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types, PMID: 23460532
4-1BB-Enhanced Expansion of CD8 + TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8 + T Cells, PMID: 28473315
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic, PMID: 34172583
For research use only. Not for human or drug use.
